Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Ramming

Showing results (81-90 of 98) with videos related to

Pageof 10
Sort By:
The Lancet. Rheumatology|January 27, 2024
<sup>68</sup>Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot studyChristina Bergmann, Jörg H W Distler, Christoph Treutlein, et al.
The Journal of Clinical Investigation|May 15, 2024
Noncanonical WNT5A controls the activation of latent TGF-β to drive fibroblast activation and tissue fibrosisThuong Trinh-Minh, Chih-Wei Chen, Cuong Tran Manh, et al.
Rheumatology (Oxford, England)|January 28, 2023
Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic SclerosisMichael Kreuter, Francesco Bonella, Norbert Blank, et al.
Chest|August 15, 2023
Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic SclerosisPia Moinzadeh, Francesco Bonella, Max Oberste, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 24, 2021
Impact of Cytokine Inhibitor Therapy on the Prevalence, Seroconversion Rate, and Longevity of the Humoral Immune Response Against SARS-CoV-2 in an Unvaccinated CohortDavid Simon, Koray Tascilar, Arnd Kleyer, et al.
Annals of the Rheumatic Diseases|July 12, 2025
Effects of different B-cell-depleting strategies on the lymphatic tissueCarlo Tur, Markus Eckstein, Laura Bucci, et al.
Nature Medicine|July 18, 2017
Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cellsSimon Rauber, Markus Luber, Stefanie Weber, et al.
Nature Communications|July 26, 2020
Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversionDavid Simon, Koray Tascilar, Gerhard Krönke, et al.
BMJ Open|January 8, 2025
Paucity of viral infection symptoms in patients with immune-mediated inflammatory diseasesMelek Yalcin Mutlu, Arnd Kleyer, Gerhard Kroenke, et al.
The Lancet. Rheumatology|August 15, 2022
Intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease: a prospective cohort studyDavid Simon, Koray Tascilar, Filippo Fagni, et al.
Pageof 10

Showing results (81-90 of 98) with videos related to

Sort By:
Pageof 10
The Lancet. Rheumatology|January 27, 2024
<sup>68</sup>Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot studyChristina Bergmann, Jörg H W Distler, Christoph Treutlein, et al.
The Journal of Clinical Investigation|May 15, 2024
Noncanonical WNT5A controls the activation of latent TGF-β to drive fibroblast activation and tissue fibrosisThuong Trinh-Minh, Chih-Wei Chen, Cuong Tran Manh, et al.
Rheumatology (Oxford, England)|January 28, 2023
Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic SclerosisMichael Kreuter, Francesco Bonella, Norbert Blank, et al.
Chest|August 15, 2023
Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic SclerosisPia Moinzadeh, Francesco Bonella, Max Oberste, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 24, 2021
Impact of Cytokine Inhibitor Therapy on the Prevalence, Seroconversion Rate, and Longevity of the Humoral Immune Response Against SARS-CoV-2 in an Unvaccinated CohortDavid Simon, Koray Tascilar, Arnd Kleyer, et al.
Annals of the Rheumatic Diseases|July 12, 2025
Effects of different B-cell-depleting strategies on the lymphatic tissueCarlo Tur, Markus Eckstein, Laura Bucci, et al.
Nature Medicine|July 18, 2017
Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cellsSimon Rauber, Markus Luber, Stefanie Weber, et al.
Nature Communications|July 26, 2020
Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversionDavid Simon, Koray Tascilar, Gerhard Krönke, et al.
BMJ Open|January 8, 2025
Paucity of viral infection symptoms in patients with immune-mediated inflammatory diseasesMelek Yalcin Mutlu, Arnd Kleyer, Gerhard Kroenke, et al.
The Lancet. Rheumatology|August 15, 2022
Intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease: a prospective cohort studyDavid Simon, Koray Tascilar, Filippo Fagni, et al.
Pageof 10